Date / Time :July 24 14:00-17:00
Venue : Taipei Nangang Exhibition Center, Hall 1 (Room 402C)
Co-organizer: LumiSTAR Biotechnology, Molecular Devices

Time	Topic	Speaker
14:00-14:10	Opening Remarks	Woolen Pan General Manager, Taiwan/Hong Kong/Macau, Molecular Devices (HK)
14:10-14:40	Modernizing Drug Discovery: Innovative Human iPSC-Derived 3D Models as Animal Testing Alternatives	Yu-Fen Chang CEO and founder, LumiSTAR Biotechnology
14:40-15:10	Leveraging High-Throughput Screening in Biomedical Research: From Principles to Practice	Ting-Jen Cheng Senior Research Specialist/Scientist, Genomics Research Center, Academia Sinica
15:10-15:35	Shifting Paradigms Together: Making Human-Relevant Model-Based Research More Accessible	Bella Tsai Product Manager, Molecular Devices (HK)
15:35-15:50	Tea Break & Networking & Group Photo
15:50-16:20	Building Better Brain Drugs: Key Considerations in Early CNS Drug Discovery	Elsa Liu Technical Director, Eurofins Panlabs Discovery Services Taiwan
16:20-16:50	Designing Microenvironments and Nanosurfaces for Controlling iPSCs and Their Application in Drug Screening and Regenerative Medicine	Li Liu Professor, Osaka University; CTO and founder, EngiTissue Design
16:50-17:00	Closing Remarks	Yu-Fen Chang  CEO and founder, LumiSTAR Biotechnology

Session Synopsis:
Join us for an illuminating symposium exploring the forefront of drug discovery innovation. This session brings together leading experts to showcase how cutting-edge human iPSC-derived 3D models, engineered microenvironments, and high-throughput screening technologies are transforming the landscape of biomedical research and therapeutic development.
Discover how advances in stem cell biology are enabling animal-free drug testing, in line with the FDA Modernization Act 3.0. Learn about the latest breakthroughs in designing nanosurfaces and microenvironments for precise control of iPSCs, and their applications in both drug screening and regenerative medicine. Gain insights into the unique challenges and opportunities in early CNS drug discovery, and see how high-throughput screening is accelerating research from principle to practice.
Whether you are a scientist, product manager, or industry leader, this session will provide actionable knowledge and a holistic perspective on the next generation of drug discovery tools and strategies.

Date / Time : July 24 08:00-17:00

Venue : Taipei Nangang Exhibition Center, Hall 1 (Room 403)

Co-organizer : Taiwan Bio Therapeutics INC.

Time	Topic	Speaker
08:00-08:30	Registration
08:30-09:00	Opening Remarks	Session Chair: Cyrus Yang
09:00-10:00	Discovery of New Immunotherapy Targets and Mechanisms Leveraging CRISPR	Arlene H. Sharpe Kolokotrones University Professor｜Harvard Medical School
10:00-10:30	Coffee Break
10:30-11:30	Tfr Regulation of Antibody Mediated Diseases	Peter T. Sage Associate Professor of Medicine｜Harvard Medical School and Brigham and Women's Hospital
11:30-13:00	Lunch Break
13:00-14:00	Therapy in Autoimmunity with a Focus on Inflammatory Bowel Disease	William A. Faubion Dean of Research, MCA｜Mayo Clinic  Executive Medical Director, CRB｜Mayo Clinic
14:00-15:00	Polymeric Particles for Immunomodulation	Jordan J. Green Herschel L. Seder Professor of Biomedical Engineering｜Johns Hopkins University School of Medicine
15:00-15:20	Coffee Break
15:20-16:20	Industry Perspective: Polyclonal Regulatory T Cell Therapy  in Solid Organ Transplantation Clinical Trials	Cyrus Yang CEO｜Taiwan Bio Therapeutics INC.
16:20-17:00	Panel Discussion & Concluding Remarks	Moderator: Cyrus Yang Panelists: Arlene H. Sharpe, Peter T. Sage, William A. Faubion, Jordan J. Green

Session Synopsis:
Regulatory T cells (Tregs) have long been recognized as central mediators of immune tolerance. What distinguishes the current moment in the field is the maturity of science and technology, which now makes it possible to translate decades of discovery into real therapeutic opportunities. With growing momentum in clinical trials and the advent of genetic engineering to enhance Treg stability, specificity, and function, Treg-based therapies are rapidly evolving from concept to clinic—offering new hope for patients with autoimmune diseases and for preventing transplant rejection.
Treg Symposium 2025 offers a timely and focused platform to explore these advances. By bringing together leading experts from both academia and industry, the symposium fosters the kind of interdisciplinary dialogue essential for addressing the scientific, clinical, and manufacturing challenges of Treg therapy. Topics will span from cutting-edge tools for understanding Treg biology and discovering new therapeutic opportunities, to clinical-stage developments of ex vivo Treg therapies and emerging strategies for in vivo Treg modulation.

Date / Time : July 24 13:00–17:30

Venue : Taipei Nangang Exhibition Center, Hall 1 (Room 503)

Co-organizer : Promega Corporation

Time	Topic	Speaker
13:00-13:30	Registration
13:30	Opening	LayPing Lee Director, Sales & Marketing Promega Corporation, Singapore
13:35-14:20	Illuminating Biologics Drug Discovery with Innovative Assays	Dr. Frank Fan Head of Biology, R&D Promega Corporation, U.S.A
14:20-15:20	The Bioluminescent Toolbox for Vaccine Characterization and mRNA Quality Control	Dr. Jamison Grailer Senior Research Scientist Promega Corporation, U.S.A
15:20-15:50	Promega Bioassays: Enabling Reliable Methodology for Research and Industrial Advancement	Dr. Mei-Wei Lin Manager Industrial Technology Research Institute
15:50-16:00	Break
16:00-16:30	Bioassays Development for Product Release and Characterization - From a CDMO Perspective	Dr. Toby Hong Associate Director of Analytical/Formulation Development & Cell Line/Cell Culture Process Development Bora Biologics
16:30-17:20	Bioluminescent Platform Technologies for Functional Characterization of Advanced Cancer Therapeutics	Dr. Jamison Grailer Senior Research Scientist Promega Corporation, U.S.A
17:20	Closing	Dr. Frank Fan Head of Biology, R&D Promega Corporation, U.S.A

Date / Time : July 25 14:00-17:00

Venue : Taipei Nangang Exhibition Center, Hall 1 (Room 402AB)
Co-organizer: Genetics Generation Advancement Corp, Taiwan Bio Industry Organization
Language : English and Chinese, No Translation Available

Time	Topic	Speaker
14:00-14:20	Guest Registration
14:20-14:35	Opening Remarks
14:35-15:20	AI-Driven Innovation in Drug Discovery	Keng-Chang Tsai Professor, National Research Institute Of Chinese Medicine Lucas Nivon CEO, Cyrus Biotechnology Andrew Pai  Principal Scientist, AnnJi Pharmaceutical
15:20-15:50	Accelerating Drug Innovation and Lab Automation through AI	Peng Hua BIOVIA Industry Process Consultant, Dassault Systèmes Wayne Chang Chairman, Lightest Biomedical Co., Ltd.
15:50-15:55	Q&A
15:55-16:10	Leveraging AI-Driven Process Optimization to Transform Biopharmaceutical Manufacturing	Jack Lim Regional Account Executive, Asia Pacific, MasterControl
16:10-16:15	Q&A
16:15-17:00	AI Platform Demonstration

Session Synopsis:
As the global AI era unfolds, artificial intelligence is rapidly transforming the biopharmaceutical landscape—from drug design and quality control to manufacturing processes. This forum, themed “AI for Bio-Pharma Integrated Practice of Design, Quality, and Manufacturing”, will spotlight the multifaceted applications and successful use cases of AI in the biopharmaceutical industry.
We are honored to bring together leading experts from both Taiwan and abroad, including representatives from the National Research Institute Of Chinese Medicine, Dassault Systèmes, and MasterControl. Together, they will explore how AI is becoming a critical driving force in the industry, unlocking new potential and future opportunities.
The forum will feature three key topics:
Harnessing AI to Decode Bio Signatures: A New Frontier in Precision Drug Development 
Accelerating Drug Innovation and Lab Automation through AI: Enhancing pharmaceutical quality management and process innovation
Leveraging AI-Driven Process Optimization to Transform Biopharmaceutical Manufacturing: How electronic batch records are reshaping manufacturing and quality systems
On behalf of the Bionet Group, we sincerely invite professionals from pharmaceutical companies, biotech firms, CRDMOs, and academic research institutions to join us for this insightful event.

Date / Time : July 25 14:00-17:00
Venue : Taipei Nangang Exhibition Center, Hall 1 (Room 404)
Organizer : Department of Industrial Technology, MOEA
Co-organizer : Metal Industries Research & Development Centre, AG CORP, KENTRON

Time	Topic	Speaker
14:00-14:30	Admission
14:30-14:35	Opening Remarks & Group Photo	Representative from Department of Industrial Technology, MOEA
14:35-15:05	U.S. AI Healthcare Market and Innovation	Dov Shamir, PhD Founding Head of Elementa Labs Mount Sinai Health System
15:05-15:35	Challenges of U.S. Market Expansion: An International Entrepreneur’s Perspective	Vivian Feng CEO of AG CORP
15:35-16:05	The Role of Accelerators in the Scaling-Up Stage	John Lynn Co-Founder of QUAY
16:05-16:35	Navigating U.S. FDA Regulations and Government Grants (e.g., SBIR/STTR)	Kenny Wang CEO of HuaMei Business Center
16:35-17:00	Panel Discussion	Moderator: Vivian Feng, CEO of Accelerator Guardian Corp. Panelists: Dov Shamir, John Lynn, Kenny Wang, Pearl Chen

Session Synopsis:
This session explores essential strategies for healthcare innovators seeking to enter the competitive U.S. market. We'll examine regulatory pathways through the FDA, reimbursement considerations, partnership opportunities, and investment landscapes unique to the American healthcare ecosystem. Experts will share insights on navigating complex stakeholder relationships, addressing market-specific challenges, and positioning your innovation for successful commercialization. Whether you're developing medical devices, biotech solutions, digital health tools, or other healthcare innovations, you'll gain practical knowledge to develop a robust U.S. market entry strategy.

Date / Time : July 25 13:30–17:00

Venue : Taipei Nangang Exhibition Center, Hall 1 (Room 503)

Co-organizer : Purple Win Co., Ltd.

Time	Topic	Speaker
13:30–14:00	Registration
14:00–14:10	Opening Remarks	Session Chair
14:10–15:10	Advanced Morphological AI Analysis as a Process Analytical Technology for Quality by Design–Driven Process Development	Ryuji Kato Associate Professor, Nagoya University, Tokai National Higher Education and Research System
15:10–15:30	Coffee Break
15:30–15:40	2nd Opening Remark
15:40–16:40	Development of robotic automation system for cell manufacturing	Masahiro Kino-oka Professor, Department of Biotechnology, The University of Osaka
16:40–17:00	Closing Discussion